REVATIO

Peak

sildenafil citrate

NDAORALFOR SUSPENSIONPriority Review
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9

Clinical Trials (5)

NCT04391868Phase 1Withdrawn

A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form

Started Jan 2021
0
Healthy
NCT01334554Phase 1/2Completed

Study of Sildenafil Citrate on Insulin Resistance in African American

Started Apr 2011
46 enrolled
Metabolic SyndromeObesity
NCT01247805Phase 1Completed

A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions

Started Jan 2011
42 enrolled
Pulmonary Arterial Hypertention
NCT00904748Phase 1Completed

A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate

Started Jan 2010
47 enrolled
Erectile Dysfunction
NCT01027117Phase 1Completed

A Relative Bioavailability Study of Revatio for the Crushed Tablets, Extemporaneously Prepared Formulation, and the Intact Tablets at 20 mg Dose in Healthy Volunteers

Started Sep 2009
18 enrolled
Healthy